Lee Eun Seong, Gao Zhonggao, Kim Dongin, Park Kyeongsoon, Kwon Ick Chan, Bae You Han
Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, 421 Wakara Way, Suite 315, UT 84108, USA.
J Control Release. 2008 Aug 7;129(3):228-36. doi: 10.1016/j.jconrel.2008.04.024. Epub 2008 May 9.
As an alternative to cell specific cancer targeting strategies (which are often afflicted with the heterogeneity of cancer cells as with most biological systems), a novel polymeric micelle constitute of two block copolymers of poly(L-lactic acid)-b-poly(ethylene glycol)-b-poly(L-histidine)-TAT (transactivator of transcription) and poly(L-histidine)-b-poly(ethylene glycol) was developed. The micelle formed via the dialysis method was approximately 95 nm in diameter and contained 15 wt.% of doxorubicin (DOX) by weight. The micelle surface hides TAT during circulation, which has the strong capability to translocate the micelle into cells, and exposes TAT at a slightly acidic tumor extracellular pH to facilitate the internalization process. The micelle core was engineered for disintegration in early endosomal pH of tumor cells, quickly releasing DOX. The ionization process of the block copolymers and ionized polymers assisted in disrupting the endosomal membrane. This processes permitted high DOX concentrations in the cytosol and its target site of the nucleus, thus increasing DOX potency in various wild and multidrug resistant (MDR) cell lines (3.8-8.8 times lower IC50 than free DOX, depending on cell line). When tested with the xenografted tumors of human ovarian tumor drug-resistant A2780/AD, human breast tumor drug-sensitive MCF-7, human lung tumor A549 and human epidermoid tumor KB in a nude mice model, all tumors significantly regressed in size by three bolus injections at a dose of DOX 10 mg equivalent/kg body per injection of DOX-loaded micelle at three day interval, while minimum weight loss was observed. This approach may replace the need for cell-specific antibodies or targeting ligands, thereby providing a general strategy for solid tumor targeting.
作为细胞特异性癌症靶向策略(与大多数生物系统一样,该策略常常受到癌细胞异质性的困扰)的替代方案,一种由聚(L-乳酸)-b-聚(乙二醇)-b-聚(L-组氨酸)-TAT(转录反式激活因子)和聚(L-组氨酸)-b-聚(乙二醇)的两种嵌段共聚物组成的新型聚合物胶束被研发出来。通过透析法形成的胶束直径约为95纳米,按重量计含有15%的阿霉素(DOX)。胶束表面在循环过程中隐藏TAT,TAT具有将胶束转运到细胞内的强大能力,在肿瘤细胞外微酸性pH条件下暴露TAT以促进内化过程。胶束核心设计为在肿瘤细胞早期内体pH值下解体,迅速释放DOX。嵌段共聚物和离子化聚合物的电离过程有助于破坏内体膜。这一过程使得胞质溶胶及其细胞核靶位点中DOX浓度较高,从而提高了DOX在各种野生型和多药耐药(MDR)细胞系中的效力(IC50比游离DOX低3.8 - 8.8倍,具体取决于细胞系)。在用裸鼠模型中的人卵巢肿瘤耐药A2780/AD、人乳腺肿瘤敏感MCF-7、人肺肿瘤A549和人表皮样肿瘤KB的异种移植肿瘤进行测试时,通过每隔三天注射一次载有DOX的胶束,每次剂量为10毫克当量/千克体重,三次大剂量注射后,所有肿瘤的大小均显著缩小,同时观察到体重减轻最小。这种方法可能无需细胞特异性抗体或靶向配体,从而为实体肿瘤靶向提供一种通用策略。